New Mexico Clinical Trials Report — July 2026

New Mexico residents who may qualify for a clinical trial should review closing studies now: 17 recruiting trials are expected to close within the next 90 days, including 5 that accept healthy volunteers. Enrollment projections can change, and screening may take time, so people who find a potential match should contact the study site promptly.

The state has 382 recruiting trials across 12 cities and 189 research sites. July brought only 1 new trial, a sharp decline from 10 in June and 5 in May. That slowdown makes the remaining openings especially important for people searching for a nearby or condition-specific opportunity.

Closing-soon studies create the most immediate opportunity

The trials nearing enrollment closure cover several medical areas, with hematologic testing representing the largest listed group. Cancer-related studies also appear among the time-sensitive opportunities, along with research involving eye health, mental health, metabolic disease, and reproductive procedures.

• Hematologic tests — 2 closing-soon trials
• Cancer — 1
• Cataract — 1
• Dietary carcinogenesis — 1
• Dilation and evacuation — 1
• Endometrial cancer — 1
• Fallopian tube cancer — 1
• Major depressive disorder — 1
• Malignancy — 1
• MASLD — 1

Five of the closing-soon trials accept healthy volunteers. That is a meaningful near-term opportunity for people without a diagnosed condition, particularly because only 1 of July’s newly opened studies accepts healthy volunteers. Anyone considering participation should verify the current recruitment status, age requirements, travel expectations, compensation, and screening procedures directly with the research team.

July’s new research focuses on chronic pain and opioid use disorder

The single new trial opened in July addresses chronic pain and opioid use disorder, two conditions that can overlap for patients seeking relief while managing medication-related risks. The study is behavioral rather than a drug trial, suggesting that researchers are examining support, decision-making, treatment engagement, or another non-medication approach.

The University of New Mexico is the named sponsor, and the study is classified outside the industry and academic categories provided in the state data. It opened in Albuquerque, giving residents in New Mexico’s largest research center a new local option. No new Phase 2 or Phase 3 drug trial, major pharmaceutical sponsor, or study enrolling more than 200 participants was identified this month.

• Chronic pain — 1 new trial
• Opioid use disorder — 1 new trial
• Behavioral research — 1 new trial
• University of New Mexico — 1 new sponsor entry

Because the data do not identify a notable Phase 2 or Phase 3 drug study for July, patients should not assume that the month’s smaller opening count means research activity has stopped. Existing trials may still be recruiting, and the state’s overall total remains substantial at 382 studies.

Albuquerque leads new activity, while statewide access remains uneven

Albuquerque was the only city listed for a July opening. That concentration is consistent with the role of large medical centers and university-affiliated research programs in clinical research, but it also means that residents outside Albuquerque may face more travel for newly opened opportunities.

Across the state, recruiting studies are distributed among 12 cities and 189 research sites. The available data do not identify the number of recruiting trials in each city, so no ranking of other locations can be established for this report. Prospective participants should search by city and travel radius rather than assuming that a trial with statewide recruitment will have a site nearby.

For people in rural communities, questions about transportation, visit frequency, remote appointments, and reimbursement should be raised before beginning screening. Some behavioral or observational studies may involve fewer in-person visits, but the specific requirements depend on each protocol.

Healthy volunteers have options, but the window is narrow

New Mexico has 32 recruiting trials that accept healthy volunteers overall. None of the 1 new July trial is open to healthy participants, making the 5 healthy-volunteer studies closing within 90 days the most urgent opportunities for people without the conditions under study.

Healthy volunteers may be asked to complete questionnaires, physical examinations, laboratory testing, imaging, behavioral sessions, or other research procedures. Eligibility can still depend on age, medications, medical history, lifestyle, and other factors. A person who appears healthy may not qualify if a screening test or prior condition conflicts with the protocol.

The month’s new study includes older adults in its eligibility criteria, but no July opening is designated as children-only, female-only, or male-only. The available figures are:

• Trials including children — 0
• Female-only trials — 0
• Male-only trials — 0
• New trials including older adults — 1
• New trials accepting healthy volunteers — 0
• Total healthy-volunteer trials recruiting statewide — 32

People with chronic pain or opioid use disorder should act quickly if the Albuquerque behavioral study fits their circumstances. Patients with cancer, endometrial cancer, fallopian tube cancer, major depressive disorder, cataracts, MASLD, or a need for hematologic testing should also prioritize the closing-soon listings, since these opportunities may disappear before another suitable study opens nearby.

A sharp midyear shift in the recruitment pipeline

New-trial activity has fluctuated considerably during 2026. The state reported 7 new trials in February, 4 in March, 2 in April, 5 in May, and 10 in June before falling to 1 in July. The August figure in the supplied trend is also 1, indicating that the pipeline may remain relatively quiet in the near term.

That pattern increases the value of monitoring existing studies rather than waiting for a new launch. Enrollment calendars are not fixed, and a trial listed as recruiting can close early when it reaches its target or pause while sites update their availability. Checking regularly and beginning prescreening early may help eligible patients avoid missing a limited opening.

Through the rest of 2026, New Mexico’s research options are likely to depend heavily on the state’s established network of sites, especially in Albuquerque, while residents elsewhere may need to plan for travel. The next new opening could bring a different condition, intervention, or sponsor profile, so patients and healthy volunteers should continue checking local listings before the current closing windows expire.